Bristol Myers Squibb stock gains on CAR-T pause and Camzyos momentum

Bristol Myers Squibb stock is holding near a recent high as investors weigh the voluntary pause in autoimmune CAR-T trials against strong Camzyos-driven share price gains and a sizable market capitalization.

Bristol Myers Squibb stock (ISIN US0897961004) is trading close to the upper end of its recent range as of September 2, 2026, with investors balancing safety concerns around paused autoimmune CAR-T trials against solid momentum from cardiology drug Camzyos and a large market capitalization in the sector.

Stock holds firm despite CAR-T safety pause

According to an overview from IT Boltwise cited by a recent Ad-hoc-news article, Bristol Myers Squibb stock is quoted at about 66.90 USD per share on the New York Stock Exchange as of September 2, 2026. The same report indicates that this price corresponds to an estimated market capitalization in the area of 136.7 billion USD, underlining the company’s weight among global biopharma players.

The Ad-hoc-news breakdown of recent trading highlights that moves between August 31, 2026 and September 1, 2026 were in a narrow band of roughly 0.2 to 0.7 percent, suggesting that headlines around CAR-T safety have not triggered abrupt volatility in Bristol Myers Squibb stock over the latest days. For investors, the key takeaway is that the share price has remained supported near 66.90 USD even as new safety data emerged.

Autoimmune CAR-T trials paused for safety review

A central catalyst for Bristol Myers Squibb in early September 2026 is the voluntary pause in certain autoimmune CAR-T trials evaluating its candidate zola-cel, following reports of serious inflammatory events in similar programs. A detailed report from CGTLive dated September 2, 2026 notes that Novartis and Bristol Myers Squibb have paused autoimmune CAR-T trials after safety events, with Bristol Myers temporarily halting at least some studies of zola-cel while continuing to evaluate the therapy’s risk profile.

CGTLive cites analysts who point to rapid manufacturing as a potential driver of increased cell expansion and associated toxicities in these programs, highlighting that indication-specific factors or a predisposition to hyperinflammatory states in certain patients may also contribute. This safety-driven pause has raised questions about timelines and risk management for next-generation autoimmune cell therapies, but so far has not translated into sharp share price losses for Bristol Myers Squibb.

Additional commentary collected by PharmExec on September 2, 2026 emphasizes that Bristol Myers Squibb has voluntarily paused enrollment rather than terminating its autoimmune CAR-T studies outright, indicating a focus on careful safety review while preserving the strategic option to resume development once risk factors are better understood.

Camzyos-driven gains and recent performance

While the CAR-T pause adds uncertainty, recent price performance has been underpinned by positive data for the cardiomyopathy therapy Camzyos. A market-focused article on Yahoo Finance titled Bristol Myers Squibb (BMY) Gains On Camzyos Data, published September 2, 2026, reports that Bristol Myers Squibb’s share price has moved to 66.92 USD, with a 90 day share price return of 22.3% and a year to date share price return of 25.2%. These figures show that over the past quarter the stock has gained 22.3 percent and since the start of 2026 it has advanced 25.2 percent, marking a clear outperformance versus many large-cap peers over the same period.

In practical terms, a share price around 66.92 USD as described by Yahoo Finance is very close to the 66.90 USD level highlighted in the Ad-hoc-news aggregation, indicating that Bristol Myers Squibb stock is trading near a short-term high rather than at distressed levels. For investors, this means that concerns about CAR-T toxicities are being weighed against concrete evidence of revenue and earnings traction in more mature franchises, with Camzyos standing out as a notable driver of sentiment.

The same Yahoo Finance analysis underscores that the recent Camzyos data has helped support valuation and expectations for Bristol Myers Squibb’s cardiology pipeline, which could partially offset any delay in autoimmune CAR-T programs. Although detailed revenue and earnings figures from the latest quarter are not cited in these day-filtered sources, the strong 90 day and year to date returns make clear that the market has rewarded Bristol Myers Squibb for its execution around Camzyos and related therapies in 2026.

Representative product: Camzyos in focus

Camzyos, a targeted treatment for obstructive hypertrophic cardiomyopathy, has become one of Bristol Myers Squibb’s flagship products in 2026 and is central to the recent improvement in its share price. As highlighted by Yahoo Finance’s coverage of Bristol Myers Squibb (BMY) Gains On Camzyos Data, investors attribute a significant portion of the 22.3 percent 90 day return and 25.2 percent year to date performance to market confidence in Camzyos’ clinical profile and commercial trajectory.

For retail investors, Camzyos illustrates how Bristol Myers Squibb’s strategy balances high-risk, high-reward areas such as autoimmune CAR-T with more established specialty medicines in cardiology and oncology. The product’s growing role in the company’s portfolio suggests that near-term valuation is being anchored not only by experimental cell therapies, but by tangible, marketed drugs that are already contributing to revenue growth and margin support.

Bristol Myers Squibb stock price and investor perspective

As of September 2, 2026, Bristol Myers Squibb stock is trading around 66.90 to 66.92 USD on the New York Stock Exchange, based on recent snapshots from Ad-hoc-news and Yahoo Finance, implying a market capitalization of roughly 136.7 billion USD. With 90 day returns of 22.3 percent and year to date gains of 25.2 percent, the stock’s performance indicates that investors currently see the CAR-T safety pause as a manageable setback within a broader, constructive story driven by drugs like Camzyos.

Bristol Myers Squibb at a glance

• Company: Bristol Myers Squibb Co.
• ISIN: US0897961004
• Ticker: BMY
• Trading venue: NYSE (primary listing)
• Price (as of September 2, 2026): 66.92 USD
• Market capitalization: 136.7 billion USD (as of September 2, 2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500